For decades, cancer patients have been told that shrinking tumors meant accepting brutal side effects as the price of survival. Now a wave of experimental therapies is starting to break that tradeoff, ...

Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination therapies hold promise, their toxicity to healthy tissue remains a major hurdle.

Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...

Ovarian cancer, often diagnosed at an advanced stage, presents significant treatment challenges because patients tend to develop resistance to conventional therapies quickly. Despite aggressive ...

With the rapid introduction of novel breast cancer therapies, recognizing and managing side effects is essential to maintain adherence and improve outcomes. As novel oral endocrine therapies and ...

As pressure increases on major pharma to bring new compounds into development, so too does pressure to make sure that these compounds are safe to test in humans. As evidenced in the TGN1214 trial last ...

Potential pharmaceuticals are typically screened for toxicity with high-throughput assays that utilize cultured cell lines and simple endpoints like cell death or inhibition of cell proliferation.

An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...

Regular blood testing to check for toxicity from standard rheumatoid arthritis drugs is recommended. However, guidelines are vague as to how frequently and for how long such testing should occur.